HC Wainwright Cuts Earnings Estimates for TuHURA Biosciences

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Equities researchers at HC Wainwright cut their Q3 2026 EPS estimates for TuHURA Biosciences in a report released on Wednesday, August 19th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.14) per share for the quarter, down from their prior estimate of ($0.13). The consensus estimate for TuHURA Biosciences’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for TuHURA Biosciences’ Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.55) EPS.

Other analysts have also issued reports about the company. Citizens Jmp restated a “market outperform” rating and issued a $9.00 target price on shares of TuHURA Biosciences in a research note on Tuesday. Citigroup began coverage on shares of TuHURA Biosciences in a research report on Monday, April 27th. They set an “outperform” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Friday, July 17th. Finally, Wall Street Zen cut shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, May 31st. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Trading Down 2.6%

Shares of HURA opened at $2.22 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.15 and a current ratio of 0.18. The company has a market cap of $141.48 million, a price-to-earnings ratio of -4.11 and a beta of -0.01. The stock has a fifty day moving average price of $2.29 and a two-hundred day moving average price of $2.06. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $3.43.

TuHURA Biosciences (NASDAQ:HURA) last announced its earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01.

Hedge Funds Weigh In On TuHURA Biosciences

Several large investors have recently made changes to their positions in HURA. Two Sigma Securities LLC acquired a new position in shares of TuHURA Biosciences during the second quarter valued at $33,000. Hsbc Holdings PLC bought a new stake in TuHURA Biosciences during the 2nd quarter worth about $69,000. Jefferies Financial Group Inc. acquired a new position in TuHURA Biosciences during the 2nd quarter valued at about $98,000. Bank of America Corp DE bought a new position in shares of TuHURA Biosciences in the 2nd quarter valued at about $99,000. Finally, Invst LLC acquired a new stake in shares of TuHURA Biosciences during the 2nd quarter worth approximately $99,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

More TuHURA Biosciences News

Here are the key news stories impacting TuHURA Biosciences this week:

• Positive Sentiment: Citizens JMP initiated coverage with a “Market Outperform” rating, indicating the firm sees potential for HURA to outperform the broader market. TuHURA Biosciences Earns Market Outperform Rating from Citizens JMP
• Neutral Sentiment: HC Wainwright projected a 2027 loss of approximately $0.15 to $0.16 per share per quarter, with a full-year loss estimate of $0.61 per share. These forecasts provide updated expectations but indicate that profitability is not expected in the near term.
• Negative Sentiment: HC Wainwright reduced its 2026 EPS estimates, lowering the expected third-quarter loss to $0.14 per share from $0.13, the fourth-quarter loss to $0.15 from $0.13, and the full-year loss to $0.55 from $0.50. The revisions suggest somewhat weaker near-term earnings prospects and are likely weighing on HURA shares.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.